Summary of medicine characteristics - LIOTHYRONINE SODIUM 20 MICROGRAMS POWDER FOR SOLUTION FOR INJECTION
1 NAME OF THE MEDICINAL PRODUCT
Liothyronine Sodium 20 micrograms Powder for Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 20 micrograms liothyronine sodium
Excipient(s) with known effect: Dextran 110
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Intravenous injection
Packed as a freeze dried white plug, in a glass vial for reconstitution with 1 or 2ml water for injection.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Liothyronine Sodium Injection is indicated for the treatment of myxoedema coma, usually in conjunction with other measures including the intravenous injection of a corticosteroid. For the treatment of less severe forms of myxoedema and for maintenance therapy, orally administered liothyronine should be used.
4.2 Posology and method of administration
Posology
5 to 20 micrograms given by slow intravenous injection and repeated at intervals of
12 hours or less if required. The minimal interval between dosing is 4 hours. An initial dose of 50 micrograms intravenously is used by some physicians, followed by further intravenous injections of 25 micrograms every 8 hours until improvement occurs. The dosage may then be reduced to 25 micrograms intravenously twice daily.
Method of Administration:
Usually given by intravenous injection, as the alkalinity of the solution may cause irritation of the tissues if given by deep intramuscular injection. The solution is prepared by adding 1 or 2ml water of injection to the ampoule and shaking gently until the solution has dissolved.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
Liothyronine sodium is contraindicated in patients with cardiovascular disorders or angina of effort and thyrotoxicosis.
4.4 Special warnings and precautions for use
Liothyronine must be given with extreme caution in myxoedema coma because too large a dose can precipitate heart failure, especially in the elderly patients and those with ischaemic heart disease.
ECG monitoring can give a useful indication of impending ischemia, however, changes in ST segment can be confused with similar changes occurring in hypothyroidism.
Liothyronine should be used with caution in patients with long-standing hypothyroidism, cardiovascular disorders, including angina, coronary artery disease, hypertension, and in the elderly, who have a greater likelihood of occult cardiac disease.
In severe and prolonged hypothyroidism, there may be decreased adrenocortical activity. When thyroid replacement therapy is started, metabolism is raised at a greater rate than adrenocortical activity, and this can result in adrenocortical insufficiency. This insufficiency may require supplemental adrenocortical steroids.
Thyroid replacement therapy may cause an increase in the dosage requirement of insulin or other anti-diabetic treatment. Care is needed in patients with diabetes mellitus and diabetes insipidus.
Liothyronine injection contains Dextran 110: Patients with rare glucose-galactose malabsorption should not take this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free.
4.5 Interaction with other medicinal products and other forms of interaction
Liothyronine sodium therapy may potentiate the action of anticoagulants (coumarins and phenindione). Anticonvulsants, such as carbamazepine and phenytoin-enhance the metabolism of thyroid hormones and may displace thyroid hormones from plasma proteins.
Initiation or discontinuation of anticonvulsant therapy may alter liothyronine dose requirements. Phenytoin levels may be increased by liothyronine.
Liothyronine raises blood sugar levels and this may upset the stability of patients receiving antidiabetic agents.
If co-administered with cardiac glycosides, adjustment of dosage of cardiac glycoside may be necessary.
Liothyronine increases receptor sensitivity to catecholamines thus accelerating the response to tricyclic antidepressants; concomitant use may precipitate cardiac arrhythmias. A number of drugs may affect thyroid function tests and this should be borne in mind when monitoring patients on liothyronine therapy.
Effects of liothyronine may be decreased by concomitant sertraline.
The effects of sympathomimetic agents (e.g. adrenaline) are also enhanced.
Liothyronine accelerates metabolism of beta-blockers like propranolol.
Metabolism of liothyronine is accelerated by rifampicin, barbituarates and primidone (may increase requirements for liothyronine in hypothyroidism).
Amiodarone may inhibit the de iodination of thyroxine to tri iodothyronine resulting in a decreased concentration of tri iodothyronine, thereby reducing the effects of thyroid hormones.
4.6 Fertility, pregnancy and lactation
Pregnancy:
The safety of liothyronine during pregnancy is not known. Any possible risk of congenital abnormalities must be weighed against the risk to the foetus of untreated hypothyroidism in the mother.
Breast-feeding:
Liothyronine is excreted into breast milk in low concentration. This may interfere with neonatal screening programmes.
Fertility:
No data available
4.7 Effects on ability to drive and use machines
Not relevant.
4.8 Undesirable effects
Side-effects are usually indicative of excessive dosage.
The undesirable effects are listed below by organ class and the following frequency convention:
Rare (>1/10,000 to <1/1,000);
Not known (cannot be estimated from the available data)
| System organ class | Frequency | Undesirable effects |
| Immune system disorders | Not Known | Hypersensitivity reactions including rash, pruritus and oedema. |
| Metabolism and nutrition disorders | Not Known | Weight loss |
| Nervous system disorders | Not Known | Tremor, restlessness, excitability, insomnia. |
| Cardiac disorders | Not Known | Anginal pain, cardiac arrhythmias, palpitations, tachycardia. |
| Gastrointestinal disorders | Not Known | Diarrhoea, vomiting |
| Musculoskeletal and connective tissue disorder | Not Known | Muscle cramps, muscle weakness. |
| Reproductive system and breast disorders | Not Known | Menstrual irregularities (relevant to maintenance therapy) |
| General disorders and administration site conditions | Not Known | Headache, flushing, fever and sweating. |
Paediatric populations:
Benign intracranial hypertension in children (Rare)
Heat intolerance and transient hair loss in children (Not Known)
Craniostenosis in infants and premature closure of epiphysis in children (Not Known)
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
4.9 OverdoseSymptoms:
Onset of signs and symptoms occurs within 12 to 24 hours and includes vomiting, diarrhoea, palpitations, anxiety, headache, flushing, agitation, hyperactivity, irritability, sweating, pyrexia, tachycardia and hypertension. In severe cases coma, convulsions, angina and ventricular arrhythmias are seen. Chronic overdose may cause myocarditis. Patients with pre-existing cardiopulmonary disease are more at risk.
Management:
Observe for at least 12 hours post ingestion if symptomatic and monitor pulse, ECG, blood pressure, and temperature.Oral activated charcoal should be used if more than 600 mcg (0.6 mg) has been taken by an adult or 10 micrograms/kg in a child within 1 hour of ingestion. Measurement of thyroid function including T3 levels is necessary if symptomatic or for prognostic purposes (non-urgent). Consider use of a beta blocker for tachycardia, sweating and hypertension. The dose should be adjusted depending on response. A normal heart rate is difficult to achieve and may result in hypotension. The aim of therapy is to keep heart rate at about 120 beat per minute. Symptomatic treatment includes the use of paracetamol for fever. Anticonvulsant therapy may be necessary in severe cases.
5 PHARMACOLOGICAL PROPERTIES
5 PHARMACOLOGICAL PROPERTIES5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Thyroid therapy, Thyroid hormones, ATC code: H03AA02
Mechanism of action
Liothyronine (L-triiodothyronine) is a naturally occurring thyroid hormone. Its biological action is qualitatively similar to that thyroxine, but the effect is more rapid in onset (in a few hours) and the effect disappears within 24 to 48 hours after stopping treatment.
5.2 Pharmacokinetic properties
Distribution
Liothyronine is less readily bound to plasma proteins than thyroxine, and about 0.5% exists in the unbound form.
Elimination
The half-life in the blood is about one to two days in euthyroidism. Thyroid hormones do not readily cross the placenta. Minimal amounts are reported excreted in breast milk.
5.3 Preclinical safety data
No additional data.
6.1 List of excipients
Dextran 110
Sodium Hydroxide
Water for Injection
6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
6.3 Shelf life
Unopened: 18 months
Following Reconstitution: Use immediately.
6.4 Special precautions for storage
Do not store above 25°C.
Keep the vial in the outer carton in order to protect from light.
For storage conditions after reconstitution of the medicinal product, see section 6.3
6.5 Nature and contents of container
4 ml Type 1, clear glass vial with bromobutyl stopper and flip-off aluminium cap.
Each outer carton contains 5 vials.
6.6 Special precautions for disposal and other handling
6.6 Special precautions for disposal and other handlingLiothyonine Powder for Injection should be prepared for injection by aseptically adding 1ml or 2ml water for injection.
The reconstituted solution should be visually inspected before use.
Only clear and colourless solutions without particles should be used.
For single use only.
Discard any unused portion of the vial in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Mercury Pharmaceuticals Ltd.,
Capital House,
85 King William Street,
London EC4N 7BL, UK
8 MARKETING AUTHORISATION NUMBER(S)
PL 12762/0176
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THEAUTHORISATION
08/10/2007